Merit Medical Acquires View Point Medical for $140M

Why It Matters

The purchase expands Merit’s therapeutic oncology offerings, positioning it to capture a growing market of over 1.3 million U.S. biopsy procedures and enhancing physician workflow. It signals consolidation in interventional radiology, potentially boosting shareholder value and patient outcomes.

Key Takeaways

• Merit pays $140M for View Point acquisition.
• OneMark system targets 1.3 million US biopsies annually.
• Projected 2027 revenue boost exceeds $16M.
• OneMark expected 20% annual sales growth, 70% margin.
• BTIG maintains buy rating on Merit Medical shares.

Pulse Analysis

The interventional radiology sector is witnessing rapid consolidation as device makers seek to offer end‑to‑end solutions for cancer diagnosis and treatment. Merit Medical, a long‑standing supplier of catheters and guide wires, has leveraged its cash reserves to acquire View Point Medical, adding a cutting‑edge ultrasound‑guided detection platform to its portfolio. This move aligns with a broader industry trend where manufacturers integrate imaging, localization, and therapeutic tools to streamline procedures and reduce patient visits.

OneMark’s FDA‑cleared technology uses real‑time ultrasound to pinpoint lesions during biopsy, complementing Merit’s existing SCOUT radar system that marks tumors pre‑operatively. Together, the two platforms give physicians multiple localization options, potentially lowering the need for separate marking procedures and improving diagnostic accuracy. With an estimated 1.3 million biopsy procedures performed annually in the United States, the combined offering addresses a sizable market opportunity and could accelerate adoption of minimally invasive oncology workflows.

Financially, the $140 million transaction—structured with $90 million cash and two $25 million contingent payments—projects an incremental $16 million revenue contribution by 2027, driven by OneMark’s anticipated 20% year‑over‑year sales growth and robust 70% gross margins. Analysts at BTIG reaffirmed a "buy" rating, citing strategic fit and overlapping customer touchpoints. As treatment protocols evolve and demand for precise, less invasive diagnostics rises, Merit’s expanded oncology suite positions it to capture market share, enhance earnings, and deliver value to shareholders and patients alike.

Deal Summary

Interventional radiology device maker Merit Medical announced the acquisition of imaging-focused firm View Point Medical for $140 million. The deal includes $90 million paid in cash at closing and two $25 million earn‑out payments, adding the FDA‑cleared OneMark Detection Imaging System to Merit’s oncology portfolio. The acquisition aims to expand Merit’s therapeutic oncology offerings and boost revenue.